Intravenous proton pump inhibitors: An evidence-based review of their use in gastrointestinal disorders

Drugs

Volumn 69, Issue 4, 2009, Pages 435-448

  Bardou, Marc ^a,b,c,d   Martin, Janet ^e   Barkun, Alan ^f  

^a INSERM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d Laboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Experimentales   (France)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

AREA UNDER THE CURVE; BOLUS INJECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; OSTEOLYSIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH PH; STRESS ULCER; THROMBOCYTOPENIA; ULCERATIVE ESOPHAGITIS; UPPER GASTROINTESTINAL BLEEDING; VERTEBRA FRACTURE;

EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; PROTON PUMP INHIBITORS;

EID: 63449140935     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969040-00004     Document Type: Review

References (71)

1. Abraham E. Acid suppression in a critical care environment: state of the art and beyond. Crit Care Med 2002; 30: S349-50
2. Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43
3. Brunner G, Luna P, Hartmann M, et al. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 1996; 69: 225-31
4. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Metaanalysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21: 677-86
5. Barkun AN, Herba K, Adam V, et al. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004; 19: 591-600
6. BarkunAN,MartelM,TouboutiY, et al. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc. In press
7. Nishina K, Mikawa K, Takao Y, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg 2000; 90: 717-21
8. Memis D, Turan A, Karamanlioglu B, et al. The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery. Anesth Analg 2003; 97: 1360-3
9. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004; 51: 757-61
10. Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo. Biochem Pharmacol 2004; 68: 2117-27
11. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59-67
12. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl. 1: 3-7
13. Wilder-Smith C, Röhss K, Bondarov P, et al. Intravenous esomeprazole 40 mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin Drug Invest 2005; 25: 517-25
14. Wilder-Smith CH, Bondarov P, Lundgren M, et al. Intravenous esomeprazole (40 mg and 20mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol 2005; 17: 191-7
15. Baker DE. Intravenous proton pump inhibitors. RevGastroenterol Disord 2006; 6: 22-34
16. UddM, Toyry J, Miettinen P, et al. The effect of regular and high doses of omeprazole on the intragastric acidity in patients with bleeding peptic ulcer treated endoscopically: a clinical trial with continuous intragastric pH monitoring. Eur J Gastroenterol Hepatol 2005; 17: 1351-6
17. Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. ANZ J Surg 2007; 77: 677-81
18. Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 2004; 70: 250-6
19. Armstrong D, Bair D, James C, et al. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11
20. Olsen KM, Devlin JW. Comparison of the enteral and intravenous lansoprazole pharmacodynamic response in critically ill patients. Aliment Pharmacol Ther 2008; 28: 326-33
21. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 2008; 134: 1836-41
22. Pais SA, Nathwani RA, Dhar V, et al. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Aliment Pharmacol Ther 2006; 23: 1607-13
23. Wilder-Smith CH, Rohss K, Bondarov P, et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther 2004; 20: 1099-104
24. Piccoli F, Ory G, Hadengue A, et al. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects: a prospective, open, randomised, two-way cross-over comparative study. Arzneimittelforschung 2007; 57: 654-8
25. Hartmann D, Eickhoff A, Damian U, et al. Effect of intravenous application of esomeprazole 40mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur J Gastroenterol Hepatol 2007; 19: 133-7
26. Pisegna JR, Sostek MB, Monyak JT, et al. Intravenous esomeprazole 40 mg versus intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther 2008; 27: 483-90
27. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. NEngl JMed 2008; 359: 928-37
28. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 286-96 446 Bardou et al.
29. Barkun AN, Cockeram AW, Plourde V, et al. Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999; 13: 1565-84
30. Metz DC, Amer F, Hunt B, et al. Lansoprazole regimens that sustain intragastric pH >6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. Aliment Pharmacol Ther 2006; 23: 985-95
31. Goletti O, Sidoti F, Lippolis PV, et al. Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastroduodenal bleeding: a prospective, randomized, controlled trial. Ital J Gastroenterol 1994; 26: 72-4
32. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding: results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32: 328-33
33. Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158: 54-8
34. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6
35. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46
36. Jensen DM, Pace SC, Soffer E, et al. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a US multicenter randomized, double-blind study. Am J Gastroenterol 2006; 101: 1991-9; quiz 2170
37. Zargar SA, Javid G, Khan BA, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol 2006; 21: 716-21
38. Tsibouris P, Zintzaras E, Lappas C, et al. High-dose pantoprazole continuous infusion is superior to somatostatin after endoscopic hemostasis in patients with peptic ulcer bleeding. Am J Gastroenterol 2007; 102: 1192-9
39. Barkun A, Racz I, van Rensburg C, et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoprazole versus ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison [abstract]. Gastroenterolgy 2004; 126: A-78
40. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: a multinational, randomised, placebo-controlled study [abstract]. Scand J Gastroenterol 2008; 48: 38
41. Andriulli A, Loperfido S, Focareta R, et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol 2008; 103: 3011-8
42. Dorward S, Sreedharan A, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006; (4): CD005415
43. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007; 356: 1631-40
44. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008; 6: 418-25
45. Tsoi KK, Lau JY, Sung JJ. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Gastrointest Endosc 2008; 67: 1056-63
46. Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24-9
47. Newton M, Kamm MA, Quigley T, et al. Symptomatic gastroesophageal reflux in acutely hospitalized patients. Dig Dis Sci 1999; 44: 140-8
48. Pratha V, Hogan DL, Lynn RB, et al. Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. Dig Dis Sci 2006; 51: 1595-601
49. Cai Q, Barrie M, Olejeme H, et al. A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Dig Dis Sci 2008; 53: 1500-5
50. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244
51. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am JGastroenterol 2002; 97: 575-83
52. Vcev A, Begic I, Ostojic R, et al. Esomeprazole versus pantoprazole for healing erosive oesophagitis. Coll Antropol 2006; 30: 519-22
53. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40mg and rabeprazole 20 mg in patients with gastrooesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531-9
54. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001; 5: 368-75
55. Terdiman JP, Ostroff JW. Gastrointestinal bleeding in the hospitalized patient: a case-control study to assess risk factors, causes, and outcome. Am J Med 1998; 104: 349-54
56. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.N Engl J Med 1994; 330: 377-81
57. Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997; 42: 1255-9
58. Conrad SA, Gabrielli A, Margolis B, et al. Randomized,double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760-5
59. Faisy C, Guerot E, Diehl JL, et al. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003; 29: 1306-13
60. Ojiako K, Shingala H, Schorr C, et al. Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care 2008; 17: 142-7
61. Somberg L, Morris Jr J, Fantus R, et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 2008; 64: 1202-10
62. Schuster DP, Rowley H, Feinstein S, et al. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am JMed 1984; 76: 623-30
63. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acidsuppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA 2005; 294: 2989-95
64. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile- associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308-13
65. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-8
66. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5
67. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008; 31: 627-36
68. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-9
69. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53
70. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-9
71. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9